21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
18:12 , Jan 11, 2019 |  BC Week In Review  |  Company News

Takeda divesting $10B in non-core assets following completed Shire acquisition

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Jan. 7 that it completed its acquisition of Shire plc (Dublin, Ireland). At the J.P. Morgan Healthcare Conference on Jan. 8 to discuss the acquisition, Takeda President and CEO...
03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed on Jan. 3 to acquire the bellwether for $74 billion....
01:23 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

FDA approves Servier's ALL therapy acquired in Shire deal

FDA approved Asparlas calaspargase pegol-mknl (formerly SHP663) from Servier (Suresnes, France) to treat acute lymphoblastic leukemia in patients ages one month to 21 years old. The pegylated L-asparaginase is approved as part of a multiagent...
14:08 , Jan 3, 2019 |  BC Extra  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed Thursday to acquire the bellwether for $74 billion. BMS cited...